What is the recommended diagnostic work‑up and treatment plan for a patient with Lambert‑Eaton myasthenic syndrome?

Lambert-Eaton Myasthenic Syndrome (LEMS): Diagnostic Work-up and Treatment

For suspected LEMS, immediately obtain anti-voltage-gated calcium channel (VGCC) antibodies, perform electromyography with repetitive nerve stimulation, and initiate aggressive cancer screening for small cell lung cancer, as approximately 50% of cases are paraneoplastic and early tumor detection directly impacts mortality. 1, 2

Clinical Recognition

LEMS presents with a distinctive triad that differentiates it from myasthenia gravis:

• Proximal leg weakness progressing craniocaudally (hip girdle predominant, spreading distally and cranially with severity)
• Reduced or absent deep tendon reflexes (areflexia)
• Autonomic dysfunction (dry mouth most common, also erectile dysfunction, orthostatic hypotension, sweating disturbances)

The weakness pattern is critical: it starts in the lower extremities and progresses upward, unlike myasthenia gravis which typically affects ocular and bulbar muscles first 2, 3, 4. Bulbar symptoms (dysarthria, dysphagia) and respiratory compromise occur later in severe cases 5.

Diagnostic Work-up

Essential Initial Testing

Serologic confirmation:

• Anti-VGCC antibodies (P/Q-type): Present in >90% of LEMS cases—this is your confirmatory test 1, 2, 6
• If VGCC antibodies are negative but clinical suspicion remains high, consider comprehensive paraneoplastic antibody panel 7

Electrophysiological studies (gold standard for functional diagnosis):

• Low-amplitude compound muscle action potentials (CMAPs) at rest
• Dramatic increment (>100%) after brief high-frequency (20-50 Hz) repetitive nerve stimulation or post-exercise facilitation 2, 4, 8
• Decrement at low-frequency (2-5 Hz) stimulation
• These findings reflect reduced acetylcholine vesicle release at the presynaptic terminal 2

Mandatory Cancer Screening

This is non-negotiable: 50-60% of LEMS cases are paraneoplastic, predominantly small cell lung cancer (SCLC) 1, 7, 2, 3

Immediate screening protocol:

• Chest CT with contrast (primary screening tool)
• Consider PET-CT for enhanced sensitivity
• Repeat screening every 3-6 months for at least 2 years if initial workup negative, as tumors may emerge later 1, 7, 3
• Older patients with smoking history have highest malignancy risk; younger non-smokers more likely have autoimmune (non-tumor) LEMS 4

Additional Baseline Assessment

• Pulmonary function tests (forced vital capacity, negative inspiratory force) to assess respiratory muscle involvement 9
• Autonomic function testing if symptoms present
• Screen for other autoimmune conditions in non-tumor LEMS 3

Treatment Algorithm

1. Tumor Treatment Takes Priority

If SCLC or other malignancy identified, oncological treatment is the primary intervention—successful cancer treatment leads to LEMS improvement in many patients 1, 4

2. Symptomatic Treatment (First-line for all patients)

3,4-Diaminopyridine (Amifampridine):

• >85% of patients achieve clinically significant benefit 4
• Mechanism: Blocks presynaptic potassium channels, prolonging action potential and increasing calcium influx, thereby enhancing acetylcholine release 3, 8
• Start immediately upon diagnosis—this is your most effective symptomatic therapy 2, 3, 8, 10

3. Immunotherapy (Add if severe weakness persists despite amifampridine)

For acute/severe cases:

• Intravenous immunoglobulin (IVIG): 2 g/kg over 5 days (0.4 g/kg/day) 1, 9
• Plasmapheresis: 3-5 sessions—induces transient improvement 1, 4, 5
• Note: Improvement is often transient; function rarely becomes completely normal 4

For chronic immunosuppression (if persistent symptoms):

• Prednisone plus azathioprine (most common combination) 3, 4
• Alternative: Cyclosporine
• Critical caveat: Improvement occurs only after many months and requires chronic administration at significant doses 4

4. Medications to Avoid

Review and discontinue drugs that worsen neuromuscular transmission 9:

• Beta-blockers
• IV magnesium
• Fluoroquinolones
• Aminoglycosides
• Macrolide antibiotics

Prognosis and Monitoring

Non-tumor LEMS:

• Normal life expectancy 2
• Complete remission uncommon—most require ongoing symptomatic treatment 2

Tumor-associated LEMS:

• Prognosis determined by SCLC progression 2
• Paradoxically, SCLC-LEMS has better prognosis than SCLC without LEMS 2

Key monitoring:

• Serial pulmonary function testing if respiratory symptoms develop 9
• Ongoing cancer surveillance in all cases
• Regular neurologic assessment to guide treatment adjustments

Critical Pitfalls to Avoid

1. Delaying cancer screening: LEMS is an early indicator of malignancy—immediate and repeated screening is essential 3, 11
2. Confusing with myasthenia gravis: LEMS has leg-predominant proximal weakness and areflexia; MG has ocular/bulbar predominance and preserved reflexes 3, 5
3. Waiting for antibody results to start treatment: Begin amifampridine based on clinical and EMG findings while awaiting serology 4, 8
4. Underestimating respiratory risk: Monitor pulmonary function, especially in severe cases 9